Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Clear Secure Inc (YOU) Price & Performance

AbbVie IncTrade
Clear Secure IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Clear Secure Inc — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Clear Secure Inc trades at $48.28 (market cap $5.28B). The key difference: AbbVie Inc is far larger — about 83× Clear Secure Inc's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.

ABBVYOU
Market Cap
$438.19B$5.28B
Sector
HealthTechnology
52-Week High
$263.58$62.36
52-Week Low
$197.38$29.61
Enterprise Value
$502.45B$4.43B
Dividend Yield
2.79%1.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Clear Secure Inc

Clear Secure (YOU) trades at $51.29, down 3.26% in 24 hours, with a bearish technical signal but strong fundamentals including 66.66% gross margins and 90.29% ROE. Recent Q2 2026 earnings beat estimates with EPS of $0.49 versus $0.40 expected, driven by double-digit revenue growth and record free cash flow. The company launched corporate memberships to expand its identity platform, enhancing business travel offerings.

Outlook is mixed: robust profitability and growth initiatives support upside, but high valuation (P/E 34.6) and technical weakness near support at $50 pose risks. Analyst consensus is balanced with 44% buy ratings, yet insider selling and competitive pressures require caution for near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Clear Secure Inc

Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.

Read more on YOU